Mylan – Recall of Valsartan-Containing Products
November 20, 2018 - Mylan announced a voluntary, consumer-level recall of several lots of valsartan, amlodipine/valsartan, and valsartan/HCTZ tablets due to the detection of trace amounts of an unexpected impurity, identified as n-nitrosodiethylamine (NDEA), found in an active pharmaceutical ingredient (API) manufactured by Mylan Laboratories Limited.
Top